Salvage surgery for advanced non-small cell lung cancer after response to gefitinib

J Thorac Cardiovasc Surg. 2010 Nov;140(5):e69-71. doi: 10.1016/j.jtcvs.2010.06.035. Epub 2010 Aug 2.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Carcinoma, Non-Small-Cell Lung / secondary
  • Carcinoma, Non-Small-Cell Lung / surgery*
  • Disease-Free Survival
  • ErbB Receptors / genetics
  • Female
  • Gefitinib
  • Humans
  • Japan
  • Kaplan-Meier Estimate
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / mortality
  • Lung Neoplasms / pathology
  • Lung Neoplasms / surgery*
  • Male
  • Middle Aged
  • Mutation
  • Neoplasm Recurrence, Local / surgery
  • Neoplasm Staging
  • Neoplasm, Residual / surgery
  • Pneumonectomy* / adverse effects
  • Pneumonectomy* / mortality
  • Protein Kinase Inhibitors / therapeutic use*
  • Quinazolines / therapeutic use*
  • Salvage Therapy
  • Time Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Quinazolines
  • EGFR protein, human
  • ErbB Receptors
  • Gefitinib